Abstract

The role of growth hormone (GH) during childhood and adulthood is well established. Once final stature is reached, GH continues to act during the transition, the period between adolescence and adulthood in which most somatic and psychological development is obtained. The achievement of peak bone mass represents the most relevant aspect of GH action during the transition period; however, equally clear is its influence on body composition and metabolic profile and, probably, in the achievement of a complete gonadal and sexual maturation. Despite this, there are still some aspects that often make clinical practice difficult and uncertain, in particular in evaluating a possible persistence of GH deficiency once final stature has been reached. It is also essential to identify which subjects should undergo re-testing and, possibly, replacement therapy, and the definition of unambiguous criteria for therapeutic success. Moreover, even during the transition phase, the relationship between GH substitution therapy and cancer survival is of considerable interest. In view of the above, the aim of this paper is to clarify these relevant issues through a detailed analysis of the literature, with particular attention to the clinical, diagnostic and therapeutic aspects.

Highlights

  • The importance and effectiveness of somatotropic hormone replacement therapy in children with low stature and/or linear growth decline associated with growth hormone deficiency (GHD) is well established

  • The end of the transition period usually corresponds with peak bone mass, which occurs at an average age of 23.1 years in males and 19.9 years in females [3]

  • A 2005 study showed that this test should not be used for the diagnosis of GHD in those adults treated with cranial irradiation (CRT) for childhood acute lymphoblastic leukemia, as it could result in a false-positive response [15]

Read more

Summary

INTRODUCTION

The importance and effectiveness of somatotropic hormone replacement therapy (rh-GH) in children with low stature and/or linear growth decline associated with growth hormone deficiency (GHD) is well established. There is a diagnostic procedural standard and therapeutic success can be evaluated based on the increase in the linear growth rate and the repositioning in the family height target. There are not the same certainties during the transition period, both in diagnostic and therapeutic terms, even though it has been widely debated in the last 2 decades [1]

Growth Hormone Deficiency During Transition
Arginine test
Body Composition
Metabolic Aspects and Cardiovascular Risk
GH and Gonadal Function
IMPACT ON QUALITY OF LIFE
WHAT IS THE RIGHT THERAPEUTIC DOSAGE DURING THE TRANSITION?
GH TREATMENT IN CANCER SURVIVORS DURING TRANSITION
Findings
CONCLUSIONS
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call